Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920218 · ClinicalTrials.gov registry record · Phase 2
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
A Phase 2 study of Herpes Zoster, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
- 11
- Study locations
NCT00920218: Completed Phase 2 study of Herpes Zoster, sponsored by GlaxoSmithKline.
NCT00920218 is a Phase 2 study of Herpes Zoster that has completed, run by GlaxoSmithKline. The registered enrollment target is 121 participants, below the 2,166-participant average among 16 other Herpes Zoster trials with a reported enrollment target (94% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00920218, a Phase 2 study of Herpes Zoster, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
Primary Outcome
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Conditions Studied
Interventions
- BIOLOGICAL Herpes Zoster Vaccine 1437173A
- BIOLOGICAL Placebo vaccine (saline)
Study Locations (11)
California
- GSK Investigational Site - Duarte
- GSK Investigational Site - San Francisco
Minnesota
- GSK Investigational Site - Minneota
- GSK Investigational Site - Rochester
North Carolina
- GSK Investigational Site - Chapel Hill
- GSK Investigational Site - Durham
Arkansas
- GSK Investigational Site - Little Rock
Massachusetts
- GSK Investigational Site - Boston
New York
- GSK Investigational Site - New York
Ohio
- GSK Investigational Site - Cleveland
Pennsylvania
- GSK Investigational Site - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2009-07-14 |
| Est. Completion | 2012-03-21 |
| Phase | Phase 2 |
What the finished NCT00920218 record still lists
NCT00920218 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, below the 2,166-participant average among 16 other Herpes Zoster trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Herpes Zoster appearing as the primary indexed condition, and to 2 interventions - of which Herpes Zoster Vaccine 1437173A is the first listed.
NCT00920218 lists 11 locations in 8 states (California, Minnesota, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00920218 about?
NCT00920218 is a clinical study titled "Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A". The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem cell transplant (HCT) recipients.
What is the current status of trial NCT00920218?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2009-07-14. Estimated completion is 2012-03-21.
What conditions does trial NCT00920218 study?
This clinical trial studies the following conditions: Herpes Zoster.
What interventions are being tested in trial NCT00920218?
The interventions under investigation include: Herpes Zoster Vaccine 1437173A (BIOLOGICAL), Placebo vaccine (saline) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00920218?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920218 being conducted?
This trial has 11 study locations across Arkansas, California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Herpes Zoster
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00920218's enrollment target sits among peer trials
121 14th of 16 higher than 3 of 16 other Herpes Zoster trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Herpes Zoster trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older
ACTIVE NOT RECRUITING · Phase 2
-
The Immunogenicity and Safety of Zostavax® and Shingrix® in Rheumatoid Arthritis Patients Using Abatacept
ACTIVE NOT RECRUITING · Phase 2
-
Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
COMPLETED · Phase 2
-
Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population
RECRUITING · Phase 1
-
Safety of Herpes Zoster Subunit (HZ/su) Vaccine During Pregnancy in Adult Women With Immunocompromised Conditions
ACTIVE NOT RECRUITING
-
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI